Zepp Health reported fourth‑quarter 2025 results that saw revenue climb 43% to $85.2 million, while gross margin hit a record 40.4%. Cash and cash equivalents rose to $112.9 million and debt fell by $58.2 million since the start of 2023. The company also confirmed that its share‑repurchase program will continue into 2026.
Revenue growth was driven by strong demand for Amazfit‑branded wearables during the Black Friday and Christmas shopping periods. The premium‑focused product mix helped the company maintain pricing power, contributing to the margin expansion.
Gross margin improvement reflects a shift toward higher‑margin Amazfit models and a more favorable mix of components. The company faced headwinds from rising memory‑chip costs, tariff pressures, and foreign‑currency fluctuations, but the mix shift offset those costs.
Net loss narrowed to $6.4 million in Q4 2025 from $22.5 million in Q4 2024, driven by revenue growth and margin gains. Management highlighted that the company’s transformation from a volume‑driven brand to a premium global brand has delivered over 50% year‑over‑year revenue growth for branded products.
For the full year 2025, Zepp Health posted revenue of $259 million, a 41.8% increase from the prior year. Management guided Q1 2026 revenue to $50.0–$55.0 million, representing a 30–43% year‑over‑year rise, and expressed confidence in sustaining growth momentum.
Investors responded positively to the results, citing the strong revenue growth, record gross margin, and narrowing net loss as evidence of effective execution and a solid path toward profitability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.